Adaptive Biotechnologies Corp reported insider sales by its chief executive and chairman, Chad M. Robins, who disposed of a combined 120,595 shares of the companys common stock in two transactions on April 6 and April 8, 2026. The total proceeds from the sales were approximately $1.76 million.
The first transaction, executed on April 6, involved the sale of 83,332 shares at a weighted average price of $14.41 per share, with transaction prices spanning $14.19 to $14.84. The second, completed on April 8, comprised 37,263 shares sold at a weighted average price of $15.19, with execution prices ranging from $15.00 to $15.53.
After these sales, Robins retains direct ownership of 2,180,518 shares of Adaptive Biotechnologies. Company filings indicate the dispositions were made pursuant to a Rule 10b5-1 trading plan that Robins established on August 11, 2025.
The stock has experienced notable appreciation over the trailing 12 months, delivering a roughly 94% return according to InvestingPro data cited in company disclosures. That same InvestingPro analysis indicates that, on a Fair Value basis, the shares may currently trade at a premium to their assessed intrinsic value.
Recent operational and market developments
Adaptive reported fourth-quarter 2025 results that topped analyst projections for both earnings and revenue. The company posted an adjusted loss per share of $0.09, an improvement versus the expected loss of $0.18, representing a 50% positive surprise versus consensus. Quarterly revenue totaled $71.7 million, ahead of the forecasted $59.33 million by about 20.85%.
Analysts and brokers updated their views following the announcement. BTIG raised its price target to $22.00, pointing to robust growth in Adaptive's Minimal Residual Disease business, which expanded 54% year-over-year in Q4 2025 and 46% for the full year. TD Cowen also lifted its price target to $21.00. Piper Sandler maintained an Overweight rating, highlighting the companys position in the MRD market and projecting clonoSEQ volume growth above 30%.
Context and limitations
The disclosed insider sales were executed under a pre-arranged 10b5-1 plan, and the firm simultaneously reported solid quarterly performance and analyst upward revisions. The InvestingPro assessment of potential overvaluation and the companys still-negative EPS are facts included in company disclosures and cited analyst notes; they signal areas market participants are watching even as revenue and MRD metrics show momentum.